ARTES receives French CIR Research Tax Credit Accreditation
Press Release | ARTES Biotechnology GmbH
NOVEMBER 21, 2017
Langenfeld, Germany: – The French Ministry of Higher Education and Research (MESR) has granted CIR research tax relief status to ARTES Biotechnology GmbH, the German-based specialist in microbial process development and technology transfer for the pharmaceutical industry.
The ‘Crédit d’Impôt Recherche’ accreditation is valid for three years and gives French companies the ability to claim tax relief on 30% of all generated costs outsourced to ARTES’ R&D services during that period.
Validated R&D provider
“We are pleased to receive this accreditation and to be approved as valid and reliable R&D provider from the French Ministry,” said ARTES Managing Director, Dr. Michael Piontek.
“It allows our customers in France to benefit from tax relief of their R&D expenses committed to us and it will help us to tie up our relationships with our present clients in France and to install new collaborations,” said Dr. Piontek.
Cell line engineering
ARTES Biotechnology is an R&D company that specializes in developing biopharmaceutical and vaccine production processes for the global pharmaceutical and biotech industries.
The company operates worldwide from its 850m2 S1 facilities in Langenfeld from where it also offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli) expression platforms, along with lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.
Recently ARTES received a new EU-based grant of patent for its well-proven virus-like-particle (VLP) antigen presentation platform METAVAX® that combined with its proprietary yeast expression technology is an excellent and unique tool for development of effective, safe and affordable vaccines.
ARTES has also enhanced the VLP based vaccine platform to develop processes especially suited for veterinary applications as part of the “Plurivax” project, funded by the German Federal Ministry of Education and Research (BMBF) as part of the 8th EuroTransBio tranche of research projects.
About ARTES Biotechnology
ARTES Biotechnology is a pharmaceutical contract research organization (CRO) that provides cell line and process development for bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms.
ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression.
This platform is applicable for large and multimeric antigens and able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization.
ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.
Dr.Melanie Piontek, Business Development Director, ARTES Biotechnology GmbH
Tel: +49 (0)217 327 587 12
Supplier: ARTES Biotechnology GmbH
Address: Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany
Tel: +49 (0) 2173 27587-0
Fax: +49 (0) 2173 27587-77